文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹

生物制剂治疗斑块状银屑病后转向湿疹表型的系统综述

Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-02-27

该系统综述检索PubMed、Medline和Embase,汇总24项研究中92例接受生物制剂(阿达木单抗、依那西普、英夫利西单抗、依奇珠单抗、司库奇尤单抗或乌司奴单抗)治疗的斑块状银屑病患者出现湿疹(含特应性湿疹)的病例。部分病例常见特应性病史、嗜酸性粒细胞增多和血清IgE升高;23例有治疗结局记录,其中14例停用或转换生物制剂。试验与观察性数据显示该不良事件发生率为1.0-12.1%。

要点

  • 抑制TNF-α及IL-17/IL-23轴的生物制剂可使银屑病患者转向湿疹表型。
  • 既往特应性素质、嗜酸性粒细胞增多和IgE升高可能与风险相关。
  • 多数病例停用相关生物制剂,但部分保守治疗亦成功。

核心结论

  • 接受抑制TNF-α和IL-17/IL-23轴生物制剂治疗的斑块状银屑病患者中,存在一致的转向特应性湿疹表型的报告。

研究设计与样本

  • 系统综述,检索PubMed、Medline和Embase数据库,纳入24项研究报告的92例患者。

主要发现

  • 92例患者使用的生物制剂包括阿达木单抗、依那西普、英夫利西单抗、依奇珠单抗、司库奇尤单抗或乌司奴单抗。
  • 部分病例常见因素包括既往特应性病史、嗜酸性粒细胞增多和血清IgE升高。
  • 23例有治疗结局记录,其中14例停用或转换生物制剂。
  • 试验数据和观察性研究中该不良事件发生率为1.0-12.1%。

关键数值与推荐

  • 管理策略包括局部或口服糖皮质激素,以及使用环孢素或阿普米司特等替代系统性药物。

临床怎么用

  • 对接受生物制剂治疗的银屑病患者应警惕湿疹样皮损,尤其是有特应性素质者。
  • 发生湿疹后可考虑停用或转换生物制剂,部分病例保守治疗有效。

局限性

  • 仅23例有治疗结局记录,多数病例缺乏长期随访数据。
  • 机制和风险因素尚未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of biologic therapies for the treatment of chronic plaque psoriasis has been linked to the development of atopic eczema, amongst other cutaneous adverse events. This can cause diagnostic confusion and create difficulty in the management of patients with plaque psoriasis. The main objective of this systematic review was to review all cases of eczema, including atopic eczema, reported in patients treated with biologics for chronic plaque psoriasis. PubMed, Medline and Embase databases were used to identify studies reporting eczema in patients treated with biologic therapy for chronic plaque psoriasis. A total of 92 patients were identified from 24 studies, with patients treated with either: adalimumab; etanercept; infliximab; ixekizumab; secukinumab; or ustekinumab. Factors common to some reported cases include: a prior history of atopy; eosinophilia; raised serum immunoglobulin E. Twenty-three had documented treatment outcomes; 14 had biologic therapy discontinued or switched. Management strategies included topical or oral corticosteroids, and treatment with alternative systemic agents such as ciclosporin or apremilast. This adverse event occurred in 1.0-12.1% of patients within trial data and observational studies. This review demonstrates that there are consistent reports of a switch to an atopic eczema phenotype from psoriasis in patients taking biologics inhibiting tumour necrosis factor alpha and the interleukin (IL)-17/IL-23 axis. The majority stopped the implicated biologic, but conservative management was successful in some cases. Those with an atopic diathesis may be more at risk. Elucidation of mechanisms and risk factors would contribute to optimal therapy selection for individual patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Al-Janabi A, Foulkes AC, Mason K, et al. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020. PMID: 31997406. doi:10.1111/jdv.16246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。